1-14 of 14
Zhengzi Qian
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Zhao Peiqi, Shu Zhao, Chen Huang, Jiesong Wang, Junqing Xu, Lanfang Li, Zhengzi Qian, Wei Li, Shiyong Zhou, Lihua Qiu, Xianming Liu, Ying Chen, Yanan Jiang, Yanbin Zheng, Daoguang Chen, Yuhuan Gao, Qingyuan Zhang, Huilai Zhang
Journal: Blood
Blood (2024) 144 (Supplement 1): 3730.
https://doi.org/10.1182/blood-2024-205438
Published: 2024
Journal Articles

Latest Update Results of Cmoep Regimen in Treatment-Naive Patients with Peripheral T-Cell Lymphoma

Jingwei Yu, Xiuhua Sun, Guangxun Gao, Li Yu, Jiesong Wang, Lihua Qiu, Zhengzi Qian, Wei Li, Huilai Zhang
Journal: Blood
Blood (2024) 144 (Supplement 1): 6403.
https://doi.org/10.1182/blood-2024-204337
Published: 2024
Journal Articles

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Yuqin Song, Zengjun Li, Ling Li, Zhengzi Qian, Keshu Zhou, Lei Fan, Peter Tan, Pratyush Giri, Zhiming Li, Melita Kenealy, Jie Jin, Wei Liu, Shafqat Inam, Yan Xie, Xia Guo, Wenduo He, Raymond Xu, Tong Li, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1719.
https://doi.org/10.1182/blood-2023-188444
Published: 2023
Journal Articles

A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

Huangming Hong, Mingzhi Zhang, Zhigang Peng, Jianzhen Shen, Yuerong Shuang, Hui Zhou, Hongqiang Guo, He Huang, Fei Li, Zhengzi Qian, Lihong Liu, Liang Wang, Wei Yang, Liling Zhang, Pengcheng He, Shen Qian, Fugen Li, Meng Li, Tongyu Lin
Journal: Blood
Blood (2023) 142 (Supplement 1): 304.
https://doi.org/10.1182/blood-2023-180372
Published: 2023
Journal Articles

CD58 Genetic Alterations and Its Contribution to Upregulation of PD-L1 and IDO Via LYN/CD22/SHP1 Axis in DLBCL

Xiyue Xu, Qingpei Guan, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Yixin Yao, Xianhuo Wang, Huilai Zhang
Journal: Blood
Blood (2023) 142 (Supplement 1): 524.
https://doi.org/10.1182/blood-2023-188468
Published: 2023
Journal Articles

Azacitidine for Injection Combined with Chidamide in Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase I Study

Jingwei Yu, Yaxiao Lu, Yixin Yao, Xianming Liu, Lanfang Li, Zhengzi Qian, Lihua Qiu, Shiyong Zhou, Xianhuo Wang, Huilai Zhang
Journal: Blood
Blood (2023) 142 (Supplement 1): 3076.
https://doi.org/10.1182/blood-2023-188801
Published: 2023
Journal Articles

PIM1 Genetic Alterations Associated with Distinct Molecular Profiles, Phenotypes and Drug Responses in Diffuse Large B-Cell Lymphoma

Xianhuo Wang, Yaxiao Lu, Sicong Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Kai Fu, Huilai Zhang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9264–9265.
https://doi.org/10.1182/blood-2022-164976
Published: 2022
Journal Articles

Comprehensive Analysis of TP53 and CD58 Mutations and Identification of Patients with Inferior Prognosis and Enhanced Immune Escape in Diffuse Large B Cell Lymphoma

Xianhuo Wang, Tingting Zhang, Yaxiao Lu, Yue Fei, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Kai Fu, Huilai Zhang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9236–9237.
https://doi.org/10.1182/blood-2022-164603
Published: 2022
Journal Articles

Immune Checkpoints Involving the PD-1/PD-L1/L2 and CD73/A2aR Axes and the Immunosuppressive Microenvironment in DLBCL

Xianhuo Wang, Tingting Zhang, Hengqi Liu, Sicong Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Kai Fu, Huilai Zhang
Journal: Blood
Blood (2022) 140 (Supplement 1): 6458–6459.
https://doi.org/10.1182/blood-2022-165060
Published: 2022
Journal Articles

Upconversion Optogenetic Engineered Bacteria System for Time-Resolved Imaging Diagnosis and Light-Controlled Lymphoma Therapy

Peiqi Zhao, Shiyong Zhou, Lihua Qiu, Lanfang Li, Zhengzi Qian, Kai Fu, Huilai Zhang
Journal: Blood
Blood (2022) 140 (Supplement 1): 6008–6009.
https://doi.org/10.1182/blood-2022-158434
Published: 2022
Journal Articles

Biological and Clinical Significance of PIM1 Genetic Alterations in Diffuse Large B-Cell Lymphoma

Xianhuo Wang, Yaxiao Lu, Yue Fei, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Kai Fu, Huilai Zhang
Journal: Blood
Blood (2021) 138 (Supplement 1): 3494.
https://doi.org/10.1182/blood-2021-150405
Published: 2021
Journal Articles

CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma

Peiqi Zhao, Huilai Zhang, MD, Kai Fu, MD PhD, Xianhuo Wang, MD, Lanfang Li, Zhengzi Qian, Lihua Qiu, Shiyong Zhou
Journal: Blood
Blood (2019) 134 (Supplement_1): 4117.
https://doi.org/10.1182/blood-2019-127666
Published: 2019
Journal Articles

Plasma Soluble Programmed Death Ligand 1 Levels Predict Clinical Response in Peripheral T-Cell Lymphomas

Xianhuo Wang, Xuhan Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Kai Fu, MD PhD, Huilai Zhang
Journal: Blood
Blood (2019) 134 (Supplement_1): 5231.
https://doi.org/10.1182/blood-2019-124266
Published: 2019
Journal Articles

Evaluation of the Prognostic Significance and Effect of NT5E-Adenosine Axis, a Novel Immune Checkpoint, in Diffuse Large B-Cell Lymphoma

Xianhuo Wang, Tingting Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Huilai Zhang, Kai Fu, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2801.
https://doi.org/10.1182/blood-2019-124233
Published: 2019